Rybelsus vs Wegovy

Rybelsus and Wegovy both contain semaglutide and are both manufactured by Novo Nordisk, but they differ substantially in formulation, dosing, approved indications, and clinical outcomes. Rybelsus is an oral tablet taken daily at doses up to 14 mg, approved for type 2 diabetes. Wegovy is a once-weekly subcutaneous injection at 2.4 mg, approved for chronic weight management and cardiovascular risk reduction. Despite sharing the same active ingredient, the injectable route delivers semaglutide far more efficiently, enabling higher effective drug exposure.

The difference in weight loss outcomes is striking. In the PIONEER 1 trial, oral semaglutide 14 mg produced approximately 4.4% mean weight loss over 26 weeks in patients with type 2 diabetes. In the STEP 1 trial, injectable semaglutide 2.4 mg produced approximately 14.9% mean weight loss over 68 weeks in adults with obesity or overweight. While these trials had different durations, patient populations, and primary endpoints -- making direct comparison imprecise -- the magnitude of difference reflects the higher systemic drug levels achievable through injection. Oral semaglutide's bioavailability is estimated at approximately 1% due to enzymatic degradation in the stomach.

Both formulations cause GLP-1 class gastrointestinal side effects. Rybelsus requires strict fasting conditions for dosing, while Wegovy requires weekly self-injection. They are approved for fundamentally different purposes: Rybelsus for glycemic control in type 2 diabetes, and Wegovy for weight management in adults with obesity or overweight with at least one weight-related condition. Patients interested in semaglutide for weight loss specifically should understand that the oral formulation is not a substitute for the injectable version in terms of expected weight reduction. A healthcare provider can help determine which formulation is appropriate based on individual goals and diagnosis.